Page last updated: 2024-12-11
penamecillin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
penamecillin : A penicillanic acid ester that is the acetoxymethyl ester of benzylpenicillin. It is a prodrug for benzylpenicillin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10250769 |
CHEMBL ID | 2106988 |
CHEBI ID | 131733 |
SCHEMBL ID | 33895 |
MeSH ID | M0066792 |
Synonyms (43)
Synonym |
---|
penamecillin |
983-85-7 |
penamecillin (usan/inn) |
D05406 |
CHEBI:131733 |
penamecilline |
acetoxymethyl benzylpenicillanate |
acetoxymethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
penamecilina |
penamecillinum |
benzylpenicillin acetoxymethyl ester |
h0p1ye5581 , |
penamecilline [inn-french] |
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-(2s-(2alpha,5alpha,6beta))-, (acetyloxy)methyl ester |
penamecillinum [inn-latin] |
penamecillina |
penamecilina [inn-spanish] |
wy 20,788 |
hydroxymethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylate, acetate (ester) |
einecs 213-571-8 |
penamecillin [usan:inn:ban] |
penamecillina [dcit] |
wy-20,788 |
penicillin g, hydroxymethyl ester, acetate |
unii-h0p1ye5581 |
wy-20788 |
CHEMBL2106988 |
penamecillin [mi] |
penamecillin [usan] |
penamecillin [inn] |
penamecillin [who-dd] |
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-((phenylacetyl)amino)-(2s-(2.alpha.,5.alpha.,6.beta.))-, (acetyloxy)methyl ester |
hydroxymethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate, acetate (ester) |
SCHEMBL33895 |
DTXSID10243547 |
(2s,5r,6r)-acetoxymethyl 3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
gtpl12808 |
havapen |
DB13739 |
acetyloxymethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate |
CS-0094810 |
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]- (2s,5r,6r)-, (acetyloxy)methyl ester |
HY-111988 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (2)
Role | Description |
---|---|
antibacterial drug | A drug used to treat or prevent bacterial infections. |
prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (2)
Class | Description |
---|---|
penicillanic acid ester | |
semisynthetic derivative | Any organic molecular entity derived from a natural product by partial chemical synthesis. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (80.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |